Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- 15 Feb 2024 Status changed from active, no longer recruiting to completed.
- 24 Mar 2023 Planned End Date changed from 1 Oct 2026 to 1 Jan 2024.
- 24 Mar 2023 Status changed from recruiting to active, no longer recruiting.